Percutaneous coronary interventions in the high-risk renal patient: Strategies for renal protection and vascular protection

Cardiology Clinics

Volumn 23, Issue 3, 2005, Pages 299-310

  McCullough, Peter A ^a   Berman, Aaron D ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; AMINOGLYCOSIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODIXANOL; IOHEXOL; LOOP DIURETIC AGENT; MEGLUMINE DIATRIZOATE; MEGLUMINE DIATRIZOATE PLUS SODIUM DIATRIZOATE; MEGLUMINE IOXAGLATE; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; NONSTEROID ANTIINFLAMMATORY AGENT; TIROFIBAN;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ANGIOPLASTY; BLEEDING DISORDER; BLOOD PRESSURE REGULATION; CARDIOGENIC SHOCK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROTECTION; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; CORONARY STENT; CORONARY VASCULAR RESISTANCE; CREATININE BLOOD LEVEL; DEATH; DIALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYDRATION; KIDNEY DISEASE; KIDNEY FUNCTION; PATHOLOGY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RADIATION; RENAL PROTECTION; REVIEW;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHRONIC DISEASE; CONTRAST MEDIA; CORONARY ARTERIOSCLEROSIS; HUMANS; KIDNEY DISEASES; RISK FACTORS; TREATMENT OUTCOME;

EID: 23344450657     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2005.03.009     Document Type: Review

References (51)

1. J. Chen, P. Muntner, and L.L. Hamm The metabolic syndrome and chronic kidney disease in US adults Ann Intern Med 140 3 2004 167 174
2. G.L. Bakris, M. Williams, and L. Dworkin Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Am J Kidney Dis 36 3 2000 646 661
3. A.V. Chobanian, G.L. Bakris, H.R. Black, and for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
4. National Kidney Foundation Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kid Dis 2 Suppl 1 2002 S46 S75
5. P.A. McCullough, S.S. Soman, and S.S. Shah Risks associated with renal dysfunction in patients in the coronary care unit J Am Coll Cardiol 36 3 2000 679 684
6. J.N. Beattie, S.S. Soman, and K.R. Sandberg Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction Am J Kidney Dis 37 6 2001 1191 1200
7. G.M. Chertow, J.M. Lazarus, and C.L. Christiansen Preoperative renal risk stratification Circulation 95 1997 878 884
8. Szczech LA, Best PJ, Crowley E, et al, for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Outcomes of patients with chronic renal insufficiency in the Bypass Angioplasty Revascularization Investigation. Circulation 2002;14;105(19):2253-8.
9. W.F. Keane, and G. Eknoyan Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation Am J Kidney Dis 33 5 1999 1004 1010
10. P.A. McCullough, and H.J. Manley Prediction and prevention of contrast nephropathy J Interven Cardiol 14 5 2001 547 558
11. P.A. McCullough Cardiorenal risk: an important clinical intersection Rev Cardiovasc Med 3 2 2002 71 76
12. P.A. McCullough, R. Wolyn, and L.L. Rocher Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality Am J Med 103 1997 368 375
13. C.M. Mangano, L.S. Diamondstone, and J.G. Ramsay Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group Ann Intern Med 128 1998 194 203
14. C.S. Rihal, S.C. Textor, and D.E. Grill Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention Circulation 105 19 2002 2259 2264
15. J. Garg, and G.L. Bakris Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes Curr Hypertens Rep 4 3 2002 185 190
16. B. Pitt, R. Segal, and F.A. Martinez Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet 349 9054 1997 747 752
17. R. Toto Angiotensin II subtype 1 receptor blockers and renal function Arch Intern Med 161 12 2001 1492 1499
18. B.M. Brenner, M.E. Cooper, and D. de Zeeuw, for the RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 12 2001 861 869
19. E.J. Lewis, L.G. Hunsicker, W.R. Clarke for the Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 12 2001 851 860
20. H.H. Parving, H. Lehnert, and J. Brochner-Mortensen for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 12 2001 870 878
21. B. Dahlof, R.B. Devereux, and S.E. Kjeldsen for the LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 9311 2002 995 1003
22. J.F. Mann, H.C. Gerstein, and J. Pogue Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Ann Intern Med 134 8 2001 629 636
23. L.Y. Agodoa, L. Appel, and G.L. Bakris for the African American Study of Kidney Disease and Hypertension (AASK) Study Group Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial JAMA 285 21 2001 2719 2728
24. P.A. McCullough, and K.R. Sandberg Epidemiology of contrast-induced nephropathy Rev Cardiovasc Med 4 Suppl 5 2003 S3 S9
25. K.J. Andersen, E.I. Christensen, and H. Vik Effects of iodinated x-ray contrast media on renal epithelial cells in culture Invest Radiol 29 11 1994 955 962
26. E.C. Keeley, and C.L. Grines Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases J Am Coll Cardiol 32 7 1998 1861 1865
27. K.M. Denton, A. Shweta, and W.P. Anderson Preglomerular and postglomerular resistance responses to different levels of sympathetic activation by hypoxia Am Soc Nephrol J 13 1 2002 27 34
28. M.A. Stevens, P.A. McCullough, and K.J. Tobin A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation J Am Coll Cardiol 33 2 1999 403 411
29. M.R. Rudnick, S. Goldfarb, L. Wexler, and P.A. Ludbrook Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study Kidney Int 47 1 1995 254 261
30. P. Aspelin, P. Aubry, and S.G. Fransson for the Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators Nephrotoxic effects in high-risk patients undergoing angiography N Engl J Med 348 6 2003 491 499
31. Davidson CJ, Laskey WK, Hermiller JB, et al. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation 2000;101(18):2172-7.
32. S. Fishbane, P.A. McCullough, and M. Rudnick Systematic review of the role of N-acetylcysteine in the prevention of contrast media-induced nephropathy J Am Soc Nephrol 14 2003 1553
33. N. Guitterez, A. Diaz, and G.C. Timmis Determinants of serum creatinine trajectory in acute contrast nephropathy J Interv Cardiol 15 5 2002 349 354
34. P.A. McCullough Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J Am Coll Cardiol 41 5 2003 725 728
35. E.C. Keeley, and P.A. McCullough Coronary revascularization in patients with end-stage renal disease: risks, benefits, and optimal strategies Rev Cardiovasc Med 4 3 2003 125 130
36. M.H. Rubenstein, L.C. Harrell, and B.V. Sheynberg Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 102 2000 2966 2972
37. L. Gruberg, R. Waksman, and A.E. Ajani The effect of intracoronary radiation for the treatment of recurrent in-stent restenosis in patients with chronic renal failure J Am Coll Cardiol 38 2001 1049 1053
38. L. Gruberg, N.J. Weissman, and A.D. Pichard Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention Am Heart J 145 2003 529 534
39. P.J. Best, R. Lennon, and H.H. Ting The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions J Am Coll Cardiol 39 2002 1113 1119
40. E.C. Keeley, R. Kadakia, and S. Soman Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes Am J Cardiol 92 5 2003 509 514
41. P.A. McCullough Acute coronary syndromes in patients with renal failure Curr Cardiol Rep 5 2003 266 270
42. H.M. Sadeghi, G.W. Stone, and C.L. Grines Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction Circulation 108 22 2003 2769 2775
43. R. Dumaine, M.L. Tanguy, and J.P. Collet A prospective multicenter registry evaluating renal failure in ACS patients (the SYCOMORE) [abstract 22053]. Eur Heart J 2003 (abstract Suppl)
44. A.J. West, S.R. Dixon, and J.K. Kahn Effectiveness of primary angioplasty for acute myocardial infarction in patients on dialysis Am J Cardiol 93 4 2004 468 470
45. S. Khanal, N. Attallah, and D.E. Smith Does statin therapy reduce contrast-induced nephropathy? An analysis from a large regional registry of contemporary percutaneous interventions J Am Coll Cardiol 45 5 2004 420
46. D. Sica The implications of renal impairment among patients undergoing percutaneous coronary intervention J Invasive Cardiol 14 Suppl B 2002 30B 37B
47. Lovenox (enoxaparin sodium) [package insert]. Paris, France: Aventis Pharmaceuticals Inc; 2004.
48. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40(11):1943-50.
49. D.P. Chew, D.L. Bhatt, and W. Kimball Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials Am J Cardiol 92 8 2003 919 923
50. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162(3):329-36.
51. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291(19):2328-34.